(Q52275725)

28 April 2018

title

Factors influencing relapse in the long-term course of schizophrenia. (English)

1 reference

28 April 2018

0 references

J L Ayuso-Gutiérrez

1

1 reference

28 April 2018

J M del Río Vega

series ordinal

2

1 reference

28 April 2018

language of work or name

English

0 references

publication date

1 December 1997

1 reference

28 April 2018

published in

Schizophrenia Research

1 reference

28 April 2018

volume

28

1 reference

28 April 2018

issue

2-3

1 reference

28 April 2018

page(s)

199-206

1 reference

28 April 2018

Schizophrenics Fully Remitted on Neuroleptics for 3–5 years—To Stop or Continue Drugs?

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900131-X

7 January 2021

Controlled Trial of Depot Fluphenazine in Out-patient Schizophrenics

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900131-X

7 January 2021

A randomised controlled trial of prophylactic neuroleptic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900131-X

7 January 2021

Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial I. Course of illness, stability of diagnosis, and the role of a special maintenance clinic

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900131-X

7 January 2021

Lithium Treatment in Schizophrenia and Schizo-Affective Disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900131-X

7 January 2021

Patterns of substance abuse in schizophrenia: nature and significance

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900131-X

7 January 2021

Mental patients' attitudes toward hospitalization: a neglected aspect of hospital tenure.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900131-X

7 January 2021

A comparative controlled trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900131-X

7 January 2021

One-year outcome of schizophrenic patients--the interaction of chronicity and neuroleptic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900131-X

7 January 2021

Predicting the "revolving door" phenomenon among patients with schizophrenic, schizoaffective, and affective disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900131-X

7 January 2021

A one year prospective study of the effect of life events and medication in the aetiology of schizophrenic relapse

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900131-X

7 January 2021

A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900131-X

7 January 2021

Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two-year relapse rates

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900131-X

7 January 2021

Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare treatment of schizophrenia. I. One-year effects of a controlled study on relapse and expressed emotion

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900131-X

7 January 2021

Further Observations on the Duration of Depot Neuroleptic Maintenance Therapy in Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900131-X

7 January 2021

The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900131-X

7 January 2021

Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilised out-patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900131-X

7 January 2021

Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900131-X

7 January 2021

Fluphenazine vs Placebo in Patients With Remitted, Acute First-Episode Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900131-X

7 January 2021

Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900131-X

7 January 2021

Treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900131-X

7 January 2021

Trial of Maintenance Therapy in Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900131-X

7 January 2021

A controlled trial of social intervention in the families of schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900131-X

7 January 2021

Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Two-year outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900131-X

7 January 2021

Intermittent pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900131-X

7 January 2021

The Nithsdale schizophrenia surveys. An overview

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900131-X

7 January 2021

One-month prevalence of mental disorders in the United States. Based on five Epidemiologic Catchment Area sites

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900131-X

7 January 2021

Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900131-X

7 January 2021

Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I. Relapse rates after one year

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900131-X

7 January 2021

Early manifestations and first-contact incidence of schizophrenia in different cultures. A preliminary report on the initial evaluation phase of the WHO Collaborative Study on determinants of outcome of severe mental disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900131-X

7 January 2021

Community management of schizophrenia. A two-year follow-up of a behavioural intervention with families.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900131-X

7 January 2021

Cost of relapse in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900131-X

7 January 2021

A depot neuroleptic withdrawal study. A controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900131-X

7 January 2021

10.1016/S0920-9964(97)00131-X

Identifiers

DOI

1 reference

28 April 2018

1 reference

28 April 2018